Efficacy of <i>Clostridium butyricum</i> Supplementation Combined with Phototherapy for Neonatal Hyperbilirubinemia: A Systematic Review and Meta-Analysis
Neonatal hyperbilirubinemia (NH), which commonly presents as jaundice, affects approximately 60% of term infants and up to 80% of preterm infants within the first week of life. This study aimed to assess the efficacy and safety of <i>Clostridium butyricum</i> (<i>C. butyricum</i...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Microorganisms |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2607/13/7/1441 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Neonatal hyperbilirubinemia (NH), which commonly presents as jaundice, affects approximately 60% of term infants and up to 80% of preterm infants within the first week of life. This study aimed to assess the efficacy and safety of <i>Clostridium butyricum</i> (<i>C. butyricum</i>) supplementation combined with phototherapy versus phototherapy alone for the treatment of NH. A systematic search of 11 databases (English, Chinese, and Korean) was conducted from 18 April 2025. Eligible randomized controlled trials (RCTs) compared <i>C. butyricum</i> plus phototherapy with phototherapy alone. Meta-analyses were performed using the mean difference (MD), standardized mean difference (SMD), and risk ratio (RR) with a 95% confidence interval (CIs). Evidence quality was evaluated using the GRADE approach. This review included 20 RCTs of 1054 neonates. Compared to phototherapy alone, <i>C. butyricum</i> supplementation significantly reduced total bilirubin (SMD = −1.54, 95% CI: −2.21 to −0.86), indirect bilirubin (SMD = −2.03, 95% CI: −2.98 to −1.07), and time to jaundice resolution (MD = −1.20 days, 95% CI: −1.66 to −0.75), and was associated with fewer adverse events (RR = 0.40, 95% CI: 0.30 to 0.55) (all <i>p</i> < 0.0001). These findings suggest that <i>C. butyricum</i> may have potential as a supportive adjunct therapy for neonatal hyperbilirubinemia. However, further studies are needed to confirm its efficacy and safety. The protocol is registered in PROSPERO (CRD420251031376). |
|---|---|
| ISSN: | 2076-2607 |